Total Funding
39
32
Total FundingSeries D raised
Growth Score
-44 pts
Heat Score
-11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
63222
OncoResponse is an immuno-oncology biotech company developing cancer immunotherapies leveraging human immune system responses.
- Bob Lechleider: Chief Medical Officer
Clifford J. Stocks: Founder and CEOPast Role: Theraclone Sciences, Chief Executive Officer
About the Company
OncoResponse is an immuno-oncology biotech company that is leveraging its proprietary human antibody platform to discover novel targets and identify fully human monoclonal antibodies as therapeutics for the treatment of cancers. It identifies genuine human antibodies to a variety of high-value targets linked with immunosuppressive myeloid biology.
OncoResponse's antibody pipeline is expected to alleviate TME immunosuppression and boost immune activation, turning cold tumors hot.
